市場調查報告書
商品編碼
1403508
Capecitabine市場至2030年的預測:按類型、適應症、分銷管道、最終用戶和地區進行的全球分析Capecitabine Market Forecasts to 2030 - Global Analysis By Type (Generic and Branded), Indication (Breast Cancer, Colorectal Cancer and Other Indications),Distribution Channel, End User and By Geography |
根據Stratistics MRC的資料,2023年全球Capecitabine市場規模為4.3636億美元,預計到2030年將達到6.9613億美元,預測期內年複合成長率為6.9%。
Capecitabine化療藥物用於治療多種癌症,包括腹部癌、大腸和乳癌。它以商品名 XelodaCapecitabine 市售,用作乳腺癌的單一療法或轉移性疾病的治療,而對於大腸,它通常與放射線治療聯合用作新輔助療法。它以其有效性、相對可控的副作用以及在提高與各種癌症作鬥爭的人們的生存率和生活品質方面的作用而聞名。
根據美國癌症協會的報告,2017年美國有約135,430例大腸直腸癌新患者和50,260例死亡。
Capecitabine是一種化療藥物,廣泛用於治療多種癌症類型,包括乳癌、大腸和胃癌。口服Capecitabine,加上其在體內轉化為活性形式的能力,使其成為一種方便而有效的癌症治療選擇。癌症患者人數不斷增加,需要增加Capecitabine等治療方案的可及性,導致市場成長,作為應對全球癌症患者不斷成長趨勢的重要治療方案。
隨著包括藥品成本在內的醫療保健成本的增加,負擔能力已成為患者和醫療保健系統關注的問題。Capecitabine是一種用於治療多種癌症的化療藥物,價格昂貴且難以獲得,這可能會影響患者的醫囑遵從性和醫療保健預算限制。個人和醫療保健提供者日益增加的經濟負擔可能會限制這種藥物的獲得,阻礙其普及,並影響癌症患者的治療選擇。
作為一種口服藥物,與標準靜脈注射相比,Capecitabine在治療期間為患者提供了更大的便利性、彈性,並提高了生活品質。此外,它需要最少的醫院就診次數,並且可以在家中自行管理,簡化了醫療服務並降低了成本。此外,癌症治療中向口服化療的轉變代表了一種進化的變化。Capecitabine是一種口服製劑,引領了這一趨勢,並透過滿足患者對更方便、更容易獲得的治療選擇的需求而在市場上立足。這將促進市場成長。
化療,包括Capecitabine等藥物,需要專門的知識和訓練。缺乏熟練的腫瘤科醫生、護士和藥劑師來管理和監督化療可能會阻礙Capecitabine的有效使用和處方。缺乏熟練的專業人員可能會導致治療效果不佳、損害患者的治療效果並限制藥物的供應。
COVID-19 大流行對整個經濟產生了顯著影響。受疫情影響,多家原料藥生產廠關閉,原料藥業務面臨許多挑戰。其中包括供應鏈中斷、原料和包裝材料採購問題以及勞動力短缺導致的營運能力下降。然而,隨著COVID-19情勢的惡化,幾種藥品的市場激增,增加了對生產相關活性原料藥的需求。
據估計,乳癌所佔比例最大。Capecitabine是一種口服化療藥物,廣泛用於治療各個階段和類型的乳癌,包括轉移性乳癌和手術後的輔助性治療。由於其有效抑制癌細胞增生且口服給藥方便,成為乳癌治療方法的首選。作為聯合治療或單一療法的一部分,Capecitabine在靶向乳癌細胞方面的功效已經確立了其重要性,並鞏固了其作為滿足乳癌患者治療需求的關鍵組成部分的地位。
預計膠囊細分市場在預測期內將出現良好的成長。Capecitabine通常以膠囊形式提供,為接受化療的患者提供了方便的口服給藥途徑。膠囊含有活性藥物,可以精確劑量且易於攝取。此外,Capecitabine的膠囊型態為醫療保健專業人員和患者提供了一種方便有效的治療各種癌症的選擇,進一步鞏固了其在製藥行業的地位,這大幅有助於我們在市場上的佔有率。
由於癌症的流行和弱勢老年人口,亞太地區在預測期內佔據了最大的市場佔有率。此外,龐大的人口基數,尤其是中國、印度和日本等國家,擁有大量患者,推動市場擴張。此外,製藥公司之間的合作夥伴關係,政府加強癌症治療的舉措以及具有成本效益的學名藥的推出進一步支持了Capecitabine在亞太地區的供應和普及。
北美是主要非專利藥公司的所在地,由於政府舉措和特殊社區的增加,預計在預測期內將實現報酬率成長。此外,該地區強大的醫療基礎設施、先進的研究設施和高癌症發病率促使Capecitabine在治療各種癌症類型(包括乳癌和大腸)中得到大量使用。有利的償付政策和醫療保健投資的增加支持了Capecitabine的可及性,使北美成為塑造Capecitabine利用和市場擴張格局的關鍵地區。
According to Stratistics MRC, the Global Capecitabine Market is accounted for $ 436.36 million in 2023 and is expected to reach $ 696.13 million by 2030 growing at a CAGR of 6.9% during the forecast period. A chemotherapy drug called capecitabine is used to treat a variety of cancers, such as abdomen, colorectal, and breast cancers. It is commercialized under the trade name of XelodaCapecitabine is used as a monotherapy or metastatic treatment for breast cancer, while in cases of colorectal cancer, the drug is mostly used as neoadjuvant therapy with radiation. It is known for its efficacy, relatively manageable side effects, and its role in improving survival rates and quality of life for individuals battling various forms of cancer.
According to the American Cancer Society report, in 2017 about 135,430 new cases and 50,260 deaths were estimated due to colon and rectum cancer in the U.S.
Capecitabine, a chemotherapy medication, is widely used in the treatment of multiple cancer types, including breast, colorectal, and gastric cancers. Its oral administration, coupled with its ability to convert into an active form within the body, makes it a convenient and potent option for cancer therapy. The expanding pool of cancer patients necessitates increased access to treatment options like Capecitabine, thereby driving its market growth as a crucial therapeutic choice in combating the rising tide of cancer cases worldwide.
As healthcare expenses rise, including medication costs, affordability becomes a concern for patients and healthcare systems. Capecitabine, a chemotherapy drug used to treat various cancers, might become less accessible due to its higher cost, impacting patient adherence and healthcare budget constraints. The increasing financial burden on individuals and healthcare providers limits access to this medication, potentially hindering its widespread use and affecting treatment options for cancer patients.
As an oral medication, capecitabine offers patients more convenience, flexibility, and a better quality of life throughout treatment than standard intravenous chemotherapy. In addition, minimal hospital visits are required, and self-administration at home is an option, which simplifies healthcare delivery and lowers expenses. Moreover, the change in cancer treatment towards oral chemotherapy is indicative of an evolutionary change. Capecitabine, with its oral formulation, is leading this trend and has positioned itself well in the market by satisfying patient demand for more convenient and accessible treatment alternatives. Thereby, it will enhance market growth.
Administering chemotherapy, including drugs like Capecitabine, requires specialised knowledge and training. The shortage of proficient oncologists, nurses, and pharmacists capable of managing and overseeing chemotherapy procedures could impede the effective use and prescription of Capecitabine. This dearth of skilled professionals might result in suboptimal treatment, compromising patient outcomes, and potentially limiting the drug's utilization.
The COVID-19 pandemic had a notable effect on the overall economy. The pandemic caused many API manufacturing plants to close during this time, which presented the API business with a number of difficulties. Some of these were supply chain disruptions, issues in locating raw materials and packaging materials, and decreased operational capacity as a result of labour shortages. But when the COVID-19 situation worsened, there was a surge in the market for several medications, which raised the need for production-related APIs.
The breast cancer segment is estimated to hold the largest share. Capecitabine, an oral chemotherapy drug, is widely utilized in various stages and types of breast cancer, including metastatic breast cancer and adjuvant therapy after surgery. Its effectiveness in inhibiting cancer cell growth and its oral administration convenience make it a preferred choice in breast cancer treatment regimens. As part of combination therapies or standalone treatment, Capecitabine's efficacy in targeting breast cancer cells has established its significance, cementing its position as a pivotal component in addressing the therapeutic needs of patients battling breast cancer.
The capsules segment is anticipated to have lucrative growth during the forecast period. Capecitabine is commonly available in capsule form, offering a convenient oral administration route for patients undergoing chemotherapy. The capsules contain the active drug, facilitating precise dosing and ease of intake. Moreover, the capsule form of Capecitabine contributes substantially to its market presence, providing both medical professionals and patients with a convenient and efficient option for managing various cancer types, further solidifying its role in the pharmaceutical landscape.
Asia Pacific commanded the largest market share during the extrapolated period due to the prevalence of cancer and vulnerable geriatric population. Additionally, the region's large population base, particularly in countries like China, India, and Japan, offers a substantial patient pool, fostering market expansion. Moreover, collaborations between pharmaceutical companies, government initiatives to enhance cancer care, and the introduction of cost-effective generic versions further propel the accessibility and adoption of Capecitabine across the Asia-Pacific region.
North America is expected to witness profitable growth over the projection period due to the presence of key generic pharmaceutical companies in this region and the rise in government initiatives and special communities. Moreover, the region's robust healthcare infrastructure, advanced research facilities, and high prevalence of cancer contribute to the substantial utilisation of Capecitabine in the treatment of various cancer types, including breast and colorectal cancers. Favourable reimbursement policies and increasing investments in healthcare support the accessibility of Capecitabine, making North America a pivotal region in shaping the landscape of Capecitabine utilisation and market expansion.
Some of the key players in the Capecitabine Market include F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan N.V., Sanofi, GSK plc, Pfizer Inc., Novartis AG, Lilly, Bayer AG, Merck & Co., Inc., Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Alkem Labs Ltd, Lupin, Armas Pharmaceuticals, Inc, Dr. Reddy's Laboratories Ltd., Cipla Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals PLC and Intas Pharmaceuticals Limited.
In December 2022, Shilpa Medicare announced that it has introduced Capecitabine (Capebel) dispersible tablet (DT) with technology of faster dispersion within 90 seconds to treat colorectal and metastatic breast cancer. This product launch may help the company to enhance their product portfolio and enhance business revenue.
In February 2021, Dr Reddy's Laboratories announced the launch of Capecitabine Tablets, USP, in the U.S. market. The product is a therapeutic equivalent generic version of Xeloda (capecitabine) tablets approved by the US Food and Drug Administration (USFDA). This product launch helped the company to enhance their product portfolio and enhance their business revenue.